Open Orphan: Sustaining commercial traction

Open Orphan PLC, a specialist pharmaceutical services company, and the world leader in the testing of vaccines and antivirals using human challenge studies, continues to make excellent progress towards maximising the capacity utilisation of its unique clinical facilities and services capabilities. The investment case centres on continuing to leverage its differentiated portfolio of assets and services, including converting a sales pipeline of non-COVID-19 related services worth over £110mln. A recently signed UK government contract valued up to £40mln is a game-changing opportunity to develop a funded COVID-19 challenge study. If this is successful, there are three government-sponsored vaccine development programmes lining up. The ongoing utility of the model is supported by the likely demand for multiple COVID-19 vaccines and antiviral treatments to meet global requirements.